护士进修杂志
護士進脩雜誌
호사진수잡지
JOURNAL OF NURSES TRAINING
2014年
17期
1542-1545
,共4页
芬太尼透皮贴%吗啡%癌痛%M eta分析
芬太尼透皮貼%嗎啡%癌痛%M eta分析
분태니투피첩%마배%암통%M eta분석
Fentanyl transdermal patches%Morphine Cancer pain%Meta-analysis
目的:评价芬太尼透皮贴和吗啡缓释片在控制中重度癌痛的效果及不良反应的情况。方法以“芬太尼透皮贴∕多瑞吉∕吗啡∕美菲康∕癌症∕癌痛∕随机∕对照”为关键词,检索公开发表的相关随机对照试验。根据澳大利亚JBI循证卫生保健中心对RCT的评价原则进行文献评价,采用RevMan 5.0软件对本系统评价关注的结局指标进行M eta分析。结果共纳入10篇文献,疼痛缓解率差异无统计学意义,头晕嗜睡、恶心呕吐、便秘发生率差异有统计学意义。结论芬太尼透皮贴剂和口服吗啡控释片治疗中重度癌痛的效果相近,但芬太尼透皮贴剂头晕嗜睡、恶心呕吐、便秘等主要不良反应的发生率较低。
目的:評價芬太尼透皮貼和嗎啡緩釋片在控製中重度癌痛的效果及不良反應的情況。方法以“芬太尼透皮貼∕多瑞吉∕嗎啡∕美菲康∕癌癥∕癌痛∕隨機∕對照”為關鍵詞,檢索公開髮錶的相關隨機對照試驗。根據澳大利亞JBI循證衛生保健中心對RCT的評價原則進行文獻評價,採用RevMan 5.0軟件對本繫統評價關註的結跼指標進行M eta分析。結果共納入10篇文獻,疼痛緩解率差異無統計學意義,頭暈嗜睡、噁心嘔吐、便祕髮生率差異有統計學意義。結論芬太尼透皮貼劑和口服嗎啡控釋片治療中重度癌痛的效果相近,但芬太尼透皮貼劑頭暈嗜睡、噁心嘔吐、便祕等主要不良反應的髮生率較低。
목적:평개분태니투피첩화마배완석편재공제중중도암통적효과급불량반응적정황。방법이“분태니투피첩∕다서길∕마배∕미비강∕암증∕암통∕수궤∕대조”위관건사,검색공개발표적상관수궤대조시험。근거오대리아JBI순증위생보건중심대RCT적평개원칙진행문헌평개,채용RevMan 5.0연건대본계통평개관주적결국지표진행M eta분석。결과공납입10편문헌,동통완해솔차이무통계학의의,두훈기수、악심구토、편비발생솔차이유통계학의의。결론분태니투피첩제화구복마배공석편치료중중도암통적효과상근,단분태니투피첩제두훈기수、악심구토、편비등주요불량반응적발생솔교저。
Objective To evaluate the effect of fentanyl transdermal patches and release morphine tablets for the control of moderate to severe cancer pain and adverse reactions by meta-analysis .Method“Fentanyl transdermal pat-ches /Durogesic /morphine /Meifeikang/cancer/cancer pain/random /control” was selected as key words ,the relevant published randomized controlled trials was retrieved based on databases .Literature was evaluated by RCT evaluation principles based on JBI evidence-based health care centers in Australia ,RevMan5 .0 software was used for meta-analysis to evaluate the system concern outcomes index .Result The meta-analysis included 10 trials .Remission rate of pain in both fentanyl transdermal patches and controlled-release oral morphine tablets was no significant difference .There were significant difference in incidence of dizziness ,drowsiness ,nausea ,vomiting and constipa-tion .Conclusion Both fentanyl transdermal and controlled-release oral morphine tablets had the same effect in the treatment of patients with moderate to severe cancer pain ,but the former might have lower incidence of adverse reac-tion .